



# **TEXAS MEDICAID VENDOR DRUG PROGRAM DRUG UTILIZATION REVIEW BOARD MEETING - RETROSPECTIVE DRUG USE PROPOSALS**

Friday, October 23, 2020

<http://www.txvendordrug.com/>

# REVISED CRITERIA: ANTI-DIABETIC AGENTS (ORAL)

- **Dosage**

- Addition of medication examples for each class drug class reviewed
- Added information about oral semaglutide (Rybelsus®)
- Removed outdated cardiovascular information about thiazolidinediones

# REVISED CRITERIA: ANTI-DIABETIC AGENTS (ORAL)

- **Dosage Continued**

- *Adults*

- Separated dosage tables based off drug classes and monotherapy vs combination therapy
      - Table 1: Monotherapy: Alpha-Glucosidase Inhibitors (AGI)
      - Table 2: Monotherapy: Biguanides
      - Table 3: Monotherapy: Bile Acid Sequestrants
      - Table 4: Monotherapy: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
      - Table 5: Monotherapy: Dopamine Agonists
      - Table 6: Monotherapy: Meglitinides
      - Table 7: Monotherapy: Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
      - Table 8: Monotherapy: Sulfonylureas
      - Table 9: Monotherapy: Thiazolidinediones (TZD)
      - Table 10: Monotherapy: Glucagon-Like Peptide-1 (GLP-1) Agonists
      - Table 11: Combination Therapies

# REVISED CRITERIA: ANTI-DIABETIC AGENTS (ORAL)

- Dosage Continued

- *Adults*

- Added information about therapies to Tables 2, 10, & 11
      - Table 2- Monotherapy: Biguanides
        - Metformin (Riomet® ER) extended release suspension
      - Table 10- Monotherapy: GLP-1 Agonists
        - Semaglutide (Rybelsus®) tablets
      - Table 11- Combination Therapies
        - Dapagliflozin/ saxagliptin/ metformin (Qternmet® XR)
        - Empagliflozin/ linagliptin/ metformin (Trijardy® XR)
        - Rosiglitazone/ metformin (Avandamet®)
        - Updated available dosage forms for dapagliflozin/saxagliptin (Qtern®), glipizide/ metformin (Metaglip®), glyburide/ metformin (Glucovance®)
        - Updated maximum dose for pioglitazone/ glimepiride (Duetact®, generics)

# REVISED CRITERIA: ANTI-DIABETIC AGENTS (ORAL)

- **Dosage Continued**
  - *Pediatrics*
    - Table 12- Monotherapy
      - Addition of metformin (Riomet® ER) extended-release oral suspension
  - *Renal Impairment*
    - Added and updated renal dosing recommendations for acarbose, metformin, canagliflozin, dapagliflozin, ertugliflozin, chlorpropamide, glyburide, and other sulfonylureas
- **References** - updated



# REVISED CRITERIA: ATTENTION DEFICIT DISORDER/ ATTENTION DEFICIT HYPERACTIVITY DISORDER MEDICATIONS

- Dosage
  - *Adults*
    - Separated dosage tables based off stimulant and non-stimulant therapies
      - Table 1: Stimulant ADHD Medications
      - Table 2: Non-Stimulant ADHD Medications



# REVISED CRITERIA: ATTENTION DEFICIT DISORDER/ ATTENTION DEFICIT HYPERACTIVITY DISORDER MEDICATIONS

- **Dosage Continued**

- *Adults*

- Added information about new therapies to Table 1

- Table 1

- Amphetamine (Dyanavel XR®)
        - Methylphenidate (Adhansia XR®)
        - Methylphenidate (Jornay PM®)
      - Removed methylphenidate (Cotempla XR ODT®) from Table 1
      - Updated dosing for amphetamine (Adzenys XR-ODT®) in Table 1

# REVISED CRITERIA: ATTENTION DEFICIT DISORDER/ ATTENTION DEFICIT HYPERACTIVITY DISORDER MEDICATIONS

- **Dosage**
  - *Pediatrics*
    - Separated dosage tables based off stimulant and non-stimulant therapies
      - Table 3: Stimulant ADHD Medications
      - Table 4: Non-Stimulant ADHD Medications Selective Norepinephrine Reuptake Inhibitors
      - Table 5: Non-Stimulant ADHD Medications Selective Alpha2A-Adrenergic Receptor Agonists
    - Addition of Psychotropic Medication Utilization Parameters for Children and Youth in Texas Public Behavioral Health (6th Version) maximum dosing recommendations



# REVISED CRITERIA: ATTENTION DEFICIT DISORDER/ ATTENTION DEFICIT HYPERACTIVITY DISORDER MEDICATIONS

- **Dosage Continued**
  - *Pediatrics*
    - Added information about new therapies to Table 3
      - Table 3
        - Amphetamine sulfate (Evekeo ODT®)
        - Methylphenidate (Adhansia XR®)
        - Methylphenidate (Cotempla XR-ODT®)
      - Table 5
        - Clonidine (Kapvay®)
- **Drug Interactions**
  - Addition of major clonidine drug interactions
- **References** - updated

# REVISED CRITERIA: GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS

- **Dosage**
  - *Adults*
    - Added information about cardiovascular benefits of GLP-1 agonists
    - Separated tables based off injectable & oral administration
      - Table 1: Injectable GLP-1 Agonists
      - Table 2: Oral GLP-1 Agonists
- **References** - updated

# REVISED CRITERIA: GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS

- **Dosage**
  - *Adults*
    - Updated # marker to identify therapies that reduce cardiovascular mortality and cardiovascular events
    - Addition of Table 2
    - Addition of semaglutide (Rybelsus®) to Table 2
- **References** - updated



# REVISED CRITERIA: PRAMLINTIDE

- **Dosage**
  - Reviewed to ensure information is still current
- **References** - updated

# REVISED CRITERIA: SEROTONIN 5-HT<sub>3</sub> RECEPTOR ANTAGONISTS FOR NAUSEA AND VOMITING (ORAL)

- **Dosage**
  - Reviewed to ensure information is still current
- **References** - updated

# REVISED CRITERIA: SUBSTANCE P/NEUROKININ1 RECEPTOR ANTAGONISTS

- **Dosage**
  - *Adults*
    - Tables separated based on monotherapy and combination therapy
      - Table 1: Oral Substance P/ Neurokinin 1 Receptor Antagonist Monotherapy
      - Table 2: Oral Substance P/ Neurokinin 1 Receptor Antagonist Combination Therapy
  - *Pediatric*
    - Updated treatment aprepitant indication to moderate to highly emetogenic chemotherapy
- **References** - updated